Form 5 - Annual statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-009699
Filing Date
2017-02-10
Accepted
2017-02-10 18:00:34
Documents
2
Period of Report
2016-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 5 SUBMISSION doc5.html 5  
1 FORM 5 SUBMISSION doc5.xml 5 4201
2 POA DOCUMENT poa.txt EX-24.5_700913 4396
  Complete submission text file 0001209191-17-009699.txt   9954
Mailing Address C/O BIOMARIN PHARMACEUTICAL INC. 371 BEL MARIN KEYS BLVD., SUITE 210 NOVATO CA 94949
Business Address
KAKKIS EMIL D (Reporting) CIK: 0001248093 (see all company filings)

Type: 5 | Act: 34 | File No.: 001-36276 | Film No.: 17594991

Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Issuer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations